Behbood Sadrolhefazi
3PUBLICATIONS
11CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Dec 05, 2025
Absorption, Metabolism, Distribution and Excretion (ADME) and Absolute Bioavailability Assessment of Zongertinib in Healthy Male Volunteers.Rolf Grempler, David Joseph, Guanfa Gan
|Oct 08, 2025
Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.Hélène Pereira, Stefan Wölke, Behbood Sadrolhefazi
|Oct 08, 2025
Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.Stefan Wölke, Behbood Sadrolhefazi, Habib Esmaeili
Pageof 1
Frequent Collaborators
2 joint publications
Fabian Müller
2 joint publications
Rolf Grempler
2 joint publications
Philipp M Roessner
1 joint publications
Simone M Blattner
1 joint publications
Dongmei Qiang
1 joint publications
Andrea Schirmer
1 joint publications
Guanfa Gan
1 joint publications
Adam M Auclair
1 joint publications
Hlaing H Maw
1 joint publications
Sven Wind
